Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 194

recruiting
3 982
countries
28
conditions
2 106

2 730 trials match your criteria

Generalised tonic-clonic seizure

Not recruiting

Study on the Effectiveness and Safety of Cenobamate for Patients Aged 12 and Older with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cenobamate

Cardiac failure chronic

Not recruiting

Study on the Effects of AZD5462 for Patients with Stable Chronic Heart Failure

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5462

Myelofibrosis

Not recruiting

Study on Extended Access to Momelotinib for Patients with Myelofibrosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Small cell lung cancer extensive stage

Not recruiting

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Charcoal, Activated

Type V hyperlipidaemia

Not recruiting

Study on Long-Term Safety and Efficacy of ARO-APOC3 for Adults with Mixed Dyslipidemia

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib

Breast cancer metastatic

Not recruiting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.